 The purpose of this study is to determine the safety and tolerability of natalizumab in adolescents ages 12-17 diagnosed with moderately to severely active Crohns disease CD. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohns disease. 